OS Fund

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.

Kenota Health specializes in the development of advanced diagnostic tools for allergy testing in humans. The company's innovative point-of-care system allows for the collection of small blood samples, which are analyzed using streamlined equipment to quickly determine allergen sensitization. This process delivers immediate test results, enabling physicians to obtain quality diagnostic information efficiently. By offering a safe, simple, and cost-effective alternative to traditional allergy testing methods, Kenota Health aims to enhance patient outcomes and streamline the diagnostic process in clinical settings.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

uBiome, Inc. was a microbial genomics company based in San Francisco, California, founded in 2012. It specialized in sequencing-based clinical microbiome tests, offering products such as SmartGut, a test for identifying pathogenic and commensal microorganisms related to infections, and SmartJane, a women's health screening test that detects various conditions including HPV and STIs. The company also provided Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. By leveraging precision sequencing combined with machine learning and artificial intelligence, uBiome aimed to enhance the understanding of the human microbiome, enabling healthcare providers to deliver more accurate diagnoses and empowering patients to manage their health more effectively. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Lygos is a biotechnology company based in Berkeley, California, established in 2011. It focuses on developing sustainable specialty chemicals by engineering microbes to convert sugars into high-value industrial chemicals. The company targets compounds where biological production offers a cost advantage over traditional petrochemical methods. Lygos employs advanced throughput screening and strain construction techniques to optimize pathways for converting inexpensive, renewable feedstock into valuable chemicals. By replacing persistent and potentially toxic chemicals with cleaner, cost-effective alternatives, Lygos aims to provide high-performing, sustainable solutions for business-to-business customers across various industries.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

NuMat Technologies, based in Skokie, Illinois, specializes in the design and integration of atomically engineered materials, specifically metal-organic frameworks (MOFs), into systems for gas delivery, separation, and purification. Founded in 2012, the company focuses on creating programmable chemistries that facilitate precision engineering and unlock new capabilities in resource management. NuMat's product portfolio includes ION-X, a solution for the safe storage and delivery of hazardous gases. The company offers a comprehensive platform for product commercialization that combines advanced material discovery software with rapid prototyping and system integration. This approach enables various industries, such as chemicals, electronics, and life sciences, to address sustainability and innovation goals through enhanced performance and cost-effective production methods.

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company focused on discovering and developing innovative small molecule therapies for complex and difficult-to-treat diseases. Utilizing an artificial intelligence-driven drug discovery platform, Aria aims to identify promising drug candidates and streamline the drug development process. The company emphasizes a redefined approach to drug discovery that significantly reduces the time required for development and increases success rates compared to traditional methods. With a diverse range of therapeutic areas in its pipeline, Aria addresses over 1,000 diseases and collaborates with biotechnology and pharmaceutical partners to enhance the discovery and development of novel drug candidates. Founded in 2014 and based in Mountain View, California, Aria Pharmaceuticals is committed to providing breakthrough treatments for patients in need.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

3T Biosciences, Inc. is an immunotherapy company established in 2017 and based in Menlo Park, California. The company focuses on developing innovative treatments for cancer and other T-cell-mediated diseases by utilizing synthetic biology and machine learning technologies. Its approach involves discovering novel targets for drug development, which aims to enhance the effectiveness of cancer therapies. Through its research and development efforts, 3T Biosciences is committed to providing healthcare professionals with advanced treatment options for patients facing cancer-related illnesses.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Synthego Corporation is a genome engineering company focused on advancing life science research and therapeutic development to improve human health. Founded in 2012 and headquartered in Redwood City, California, Synthego offers a comprehensive platform that integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology. The company's product portfolio includes engineered cells, CRISPR kits, and bioinformatics tools designed for various applications such as pathway analysis, target validation, disease modeling, and diagnostics. By leveraging machine learning and automation, Synthego enables researchers in biotechnology and academia to conduct efficient and precise gene editing, facilitating rapid advancements in drug discovery and development. The company serves a global customer base, distributing its products through various channels, including online sales and partnerships in multiple countries.

Lygos is a biotechnology company based in Berkeley, California, established in 2011. It focuses on developing sustainable specialty chemicals by engineering microbes to convert sugars into high-value industrial chemicals. The company targets compounds where biological production offers a cost advantage over traditional petrochemical methods. Lygos employs advanced throughput screening and strain construction techniques to optimize pathways for converting inexpensive, renewable feedstock into valuable chemicals. By replacing persistent and potentially toxic chemicals with cleaner, cost-effective alternatives, Lygos aims to provide high-performing, sustainable solutions for business-to-business customers across various industries.

Prospect Bio is a synthetic biology company based in Brisbane, California, that focuses on developing biosensors for the detection of small molecules. These biosensors, which utilize living cells, offer a cost-effective, scalable, and field-deployable alternative to traditional testing methods that often rely on expensive and slow laboratory equipment. The company's innovative approach aims to transform testing processes across various industries, driven by the need for improved quality control and compliance with regulatory standards. Prospect Bio collaborates with a diverse range of partners, including major players in the wine industry, agriculture, and prenatal diagnostics. The company has raised $2.8 million from prominent investors, which supports its mission to enhance biosensor technology and pathway discovery through the integration of automation, computation, and synthetic biology.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

MetaMixis Inc. is a biotechnology company based in Vancouver, Canada, founded in 2012. The company focuses on developing enzymes and metabolic pathways for microorganisms that produce chemicals. MetaMixis creates biosensors that leverage natural environmental processes to detect biochemical transformations. Additionally, it screens diverse environmental DNA libraries to generate a portfolio of enzymes and pathways capable of performing specific transformations. The founding team combines expertise in synthetic biology, environmental genomics, and bioinformatics, with the goal of advancing the bioeconomy through innovative enzyme and pathway discovery. The company has also established a knowledgeable board to guide its development and growth.

Kenota Health specializes in the development of advanced diagnostic tools for allergy testing in humans. The company's innovative point-of-care system allows for the collection of small blood samples, which are analyzed using streamlined equipment to quickly determine allergen sensitization. This process delivers immediate test results, enabling physicians to obtain quality diagnostic information efficiently. By offering a safe, simple, and cost-effective alternative to traditional allergy testing methods, Kenota Health aims to enhance patient outcomes and streamline the diagnostic process in clinical settings.

Kenota Health specializes in the development of advanced diagnostic tools for allergy testing in humans. The company's innovative point-of-care system allows for the collection of small blood samples, which are analyzed using streamlined equipment to quickly determine allergen sensitization. This process delivers immediate test results, enabling physicians to obtain quality diagnostic information efficiently. By offering a safe, simple, and cost-effective alternative to traditional allergy testing methods, Kenota Health aims to enhance patient outcomes and streamline the diagnostic process in clinical settings.

NuMat Technologies, based in Skokie, Illinois, specializes in the design and integration of atomically engineered materials, specifically metal-organic frameworks (MOFs), into systems for gas delivery, separation, and purification. Founded in 2012, the company focuses on creating programmable chemistries that facilitate precision engineering and unlock new capabilities in resource management. NuMat's product portfolio includes ION-X, a solution for the safe storage and delivery of hazardous gases. The company offers a comprehensive platform for product commercialization that combines advanced material discovery software with rapid prototyping and system integration. This approach enables various industries, such as chemicals, electronics, and life sciences, to address sustainability and innovation goals through enhanced performance and cost-effective production methods.

Mozio, Inc. operates an online airport transportation search and booking engine, enabling travelers to find and reserve various ground transportation options, including shared ride shuttles, private vans, taxis, limousines, and SUVs from airports across the globe. The platform aggregates local transportation services in regions such as the United States, Canada, Latin America, Europe, and Asia, simplifying the process of navigating from the airport to the final destination. Founded in 2012 and based in San Francisco, Mozio also offers API and affiliate programs, allowing travel websites and agents to sell transportation services. The company's mission is to enhance the travel experience by providing users with comprehensive information and the best deals for their ground transportation needs.

3Scan, Inc. specializes in developing advanced microscopy tools and software for automated tissue sectioning and imaging, primarily aimed at enhancing large-scale sample analysis and 3D visualizations. Founded in 2010 and based in San Francisco, California, the company focuses on addressing diseases that manifest at the tissue level, including cancer, heart disease, and neurodegenerative disorders. By integrating automation, machine learning, and computer vision, 3Scan's technology enables researchers and medical professionals to achieve greater throughput, improved quantification, and extensive image analysis compared to traditional histopathology methods. This data-driven approach aims to deepen the understanding of tissue biology, facilitating the discovery of new diagnostics and therapeutics. 3Scan was acquired by Transcriptic, Inc. in 2019.

Elysium Health, Inc. develops and produces health supplements focused on cellular health, long-term brain health, and biological age testing. Founded in 2014 and based in New York, the company sells its products online, aiming to enhance health and longevity through scientifically backed solutions. Elysium collaborates with scientists, clinicians, and health professionals globally to identify and formulate natural compounds. Its flagship product features a proprietary combination of ingredients designed to support overall well-being at the cellular level, addressing contemporary health challenges with a foundation in scientific research.

Planetary Resources is focused on the exploration and utilization of asteroids to unlock essential natural resources for humanity. The company provides services aimed at commercial deep space exploration, specifically targeting asteroids for raw materials such as water and precious metals. By extracting water from asteroids, Planetary Resources aims to support the in-space economy by producing rocket fuel and providing consumable water for future space habitation. This initiative is pivotal for enabling human expansion into space and contributing to the development of a sustainable space economy, ultimately helping humanity become a multi-planetary species.

Nanoly Bioscience, Inc. is a biotechnology company that specializes in developing polymers designed to stabilize temperature-sensitive molecules, such as vaccines and therapeutics, during storage and transportation. Founded in 2012 and headquartered in Denver, Colorado, Nanoly's innovative polymer technology allows these sensitive products to survive without refrigeration, thereby extending their shelf life and eliminating the need for temperature-controlled storage in certain cases. This advancement is particularly significant for the distribution of vaccines and protein-based therapeutics, offering a practical solution to the challenges posed by conventional cold chain logistics.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Pivot Bio is a biotechnology company founded in 2010 and based in Emeryville, California, that focuses on enhancing crop nutrition through the use of engineered microbes. The company leverages its deep understanding of the plant microbiome, employing engineering principles and data science to map microbial dynamics and develop beneficial traits. Pivot Bio's proprietary ON Technology utilizes naturally occurring microbes to provide crops with essential nutrients, particularly nitrogen, which is crucial for growth. This innovative approach aims to replace synthetic nitrogen fertilizers, thereby reducing the environmental impact associated with conventional farming practices. By enhancing crops' ability to capture and metabolize atmospheric nitrogen, Pivot Bio seeks to lower farming costs, improve crop yields, and contribute to a sustainable agricultural future that benefits both the planet and food supply.

Viv Labs, Inc. is an artificial intelligence company based in San Jose, California, founded in 2012. It specializes in developing a platform that facilitates the creation of intelligent, conversational interfaces, allowing users to interact seamlessly with various devices, services, and applications. The platform is designed for developers, enabling them to integrate their products into a universal digital assistant capable of understanding and responding to a wide range of spoken requests. In May 2014, the company changed its name from Six Five Labs, Inc. and has since operated as a subsidiary of Samsung Research America, Inc. Viv's technology continuously learns and adapts, enhancing its ability to provide intelligent interactions across diverse platforms.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Lucira Health, Inc. is a medical technology company based in Emeryville, California, that specializes in the development and commercialization of innovative infectious disease test kits. Founded in 2013, the company focuses on creating accessible and user-friendly testing solutions, including a disposable COVID-19 test kit designed for home use. This kit provides centralized-laboratory-accurate molecular testing in a compact format that operates on two AA batteries. It connects consumers to treatment options through a mobile application and offers a dual testing capability to determine whether viral respiratory symptoms are caused by COVID-19 or influenza. Lucira Health aims to enhance the accessibility and efficiency of infectious disease diagnostics.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Atomwise, Inc. is a biotechnology company based in San Francisco that specializes in using deep learning artificial intelligence for small molecule drug discovery. Founded in 2012, Atomwise developed the AtomNet platform, which enables virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical approach that leverages experimental affinity measurements and protein structures. The company focuses on addressing over 600 unique disease targets and has established partnerships with more than 250 organizations, including pharmaceutical and biotechnology firms. Atomwise's technology has been recognized for its ability to unlock previously undruggable targets, and the company has raised significant funding to support its mission of accelerating drug discovery and development.

Emerald Cloud Lab, Inc. is a biotechnology company based in South San Francisco, California, that develops an innovative life sciences laboratory designed to streamline and enhance scientific research. Founded in 2010 by two scientists, the company aims to address the challenges of rising research and development costs in the pharmaceutical industry by automating and optimizing laboratory workflows. The Emerald Cloud Laboratory provides a comprehensive facility that manages various aspects of laboratory operations, including method design, materials logistics, sample preparation, instrument operation, data acquisition, analysis, and waste disposal. This approach allows researchers to focus on designing experiments and analyzing results rather than on routine tasks, thereby accelerating the pace of innovation in life sciences. Emerald's commitment to improving laboratory efficiency reflects a vision of driving significant advancements in research and development akin to the technological shifts seen in the semiconductor industry.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Tempo Automation is a software-accelerated electronics manufacturer that revolutionizes how companies develop and launch new electronic products. Its innovative manufacturing platform streamlines the complex process of printed circuit board assembly (PCBA), offering exceptional speed, quality, and transparency during critical phases of product development, particularly from prototyping to new product introduction. This automated approach leverages data-driven intelligence and a fully digital process, enabling customers to respond swiftly to market demands. Tempo Automation serves a diverse range of industries, including aerospace, medical technology, semiconductor, industrial technology, and automotive, providing these leading innovators with a competitive edge and the ability to deliver advanced products efficiently.

Eat Just, Inc., founded in 2011 and based in San Francisco, California, focuses on creating plant-based food products aimed at improving the food system. The company offers a variety of items, including plant-based scrambled eggs, flavored mayonnaise, dressings, cookie doughs, and meat alternatives. Their flagship product, JUST Egg, has garnered significant recognition, being featured in lists such as Popular Science's "100 Greatest Innovations." Eat Just emphasizes innovation through a unique discovery platform for food ingredients, combining scientific research with culinary expertise from Michelin-starred chefs. The company has been acknowledged in various prestigious lists, including Fast Company’s "Most Innovative Companies" and Entrepreneur’s "100 Brilliant Companies."

Plethora Corporation, founded in 2012 and headquartered in San Francisco, California, specializes in precision machining services, particularly in CNC machining, milling, and turning. The company works with materials such as aluminum alloys, copper alloys, plastics, steels, and stainless steels. Plethora serves a diverse range of industries, including robotics, automotive, aerospace, and consumer packaged goods, primarily within the United States. Utilizing advanced robotics and proprietary software, Plethora transforms customer designs into custom parts and offers design feedback directly from clients' CAD models, enhancing the manufacturing process. Additionally, Plethora maintains an office in Marietta, Georgia, to support its operational capabilities.

Developer of MicroRNA profiling technology designed to detect genetic fragments in the blood or tissue. The company's platform leverages a proprietary digital microfluidics technology to automate manually intensive experimental workflows on a low-cost cartridge, enabling medical practitioners to have access to accurate, affordable, and minimally invasive molecular testing.

uBiome, Inc. was a microbial genomics company based in San Francisco, California, founded in 2012. It specialized in sequencing-based clinical microbiome tests, offering products such as SmartGut, a test for identifying pathogenic and commensal microorganisms related to infections, and SmartJane, a women's health screening test that detects various conditions including HPV and STIs. The company also provided Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. By leveraging precision sequencing combined with machine learning and artificial intelligence, uBiome aimed to enhance the understanding of the human microbiome, enabling healthcare providers to deliver more accurate diagnoses and empowering patients to manage their health more effectively. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019.

uBiome, Inc. was a microbial genomics company based in San Francisco, California, founded in 2012. It specialized in sequencing-based clinical microbiome tests, offering products such as SmartGut, a test for identifying pathogenic and commensal microorganisms related to infections, and SmartJane, a women's health screening test that detects various conditions including HPV and STIs. The company also provided Explorer kits for citizen scientists and researchers, as well as SmartFlu, a clinical respiratory test. By leveraging precision sequencing combined with machine learning and artificial intelligence, uBiome aimed to enhance the understanding of the human microbiome, enabling healthcare providers to deliver more accurate diagnoses and empowering patients to manage their health more effectively. However, uBiome faced financial difficulties and filed for Chapter 11 bankruptcy in September 2019, which was later converted to Chapter 7 on October 11, 2019.

Vicarious is an artificial intelligence company founded in 2010 by Dr. Dileep George and D. Scott Phoenix. The company develops neuro and cognitive science-based technologies aimed at creating general intelligence for robots by mimicking the functions of the human brain. Its innovative algorithmic architecture seeks to achieve human-level intelligence in areas such as vision, language, and motor control. Vicarious focuses on visual perception challenges, including recognition, segmentation, and scene parsing. This technology enables robot manufacturers to produce robots with enhanced intelligence and improved task efficiency.

Human Longevity (HLI) is a genomic-based health intelligence company focused on proactive healthcare and enhancing quality of life. Founded in 2013 and headquartered in San Diego, California, HLI utilizes a comprehensive database of genomic and phenotypic data, combined with advanced machine learning techniques, to drive medical discoveries and transform healthcare practices. The company operates multiple business areas, including the HLI Health Nucleus, a clinical research center that employs whole-genome sequencing, advanced imaging, and curated personal health data to provide an in-depth understanding of individual health. HLI's platform also addresses age-related decline in stem cell function and focuses on major health issues such as cancer, diabetes, obesity, heart and liver diseases, and dementia. By integrating DNA sequencing with expert analysis, HLI aims to empower individuals to take control of their health and shift medical care from a reactive to a proactive approach.

Cleversafe, Inc. specializes in developing web-scale storage solutions tailored for the demands of hyperscale environments. Founded in 2004 and based in Chicago, Illinois, the company provides a range of services including enterprise storage, content repository, and Storage-as-a-Service. Cleversafe's technology addresses the rapid growth of unstructured data, which is increasing by 60-80 percent annually, by enabling businesses to store, manage, and access data at petabyte scale and beyond. The company's solutions are designed for various industries, including financial services, healthcare, media, oil and gas, and government, ensuring significant improvements in economic efficiency, security, and operational simplicity. As of November 2015, Cleversafe operates as a subsidiary of International Business Machines Corporation.

LightSail Energy specializes in the development of advanced energy storage systems that utilize compressed air technology. By focusing on grid-scale applications, the company aims to enhance the efficiency and reliability of energy storage, particularly for renewable sources such as solar and wind. This shift from vehicle-based technology to modernizing the electrical grid allows clients to access low-cost and effective energy storage solutions, enabling them to meet demand for clean energy. Through its innovative approach, LightSail Energy is working to transform how energy is stored and delivered worldwide.